SAN CARLOS, Calif., Feb. 21 Nektar Therapeutics(Nasdaq: NKTR) will announce its financial results for the fourth quarter andyear ended December 31, 2007 on Wednesday, February 27, 2008, after the closeof U.S.-based financial markets. Howard Robin, president and chief executiveofficer, will host a conference call for analysts and investors beginning at5:00 p.m. Eastern Time (ET).
Investors can access the press release and a live audio-only Webcast ofthe conference call through a link that is posted on the Investor Relationssection of the Nektar website: http://www.nektar.com. The web broadcast of theconference call will be available for replay through Wednesday, March 12,2008.
An audio replay will also be available shortly following the call throughWednesday, March 12, 2008 and can be accessed by dialing (888) 286-8010(U.S.); or (617) 801-6888 (international) with a passcode of 92959414.
In the event that any non-GAAP financial measure is discussed on theconference call that is not described in the press release, relatedinformation will be made available on the Investor Relations page at theNektar website as soon as practical after the conclusion of the conferencecall.
Nektar Therapeutics is a biopharmaceutical company that develops andenables differentiated therapeutics with its industry-leading PEGylation andpulmonary drug development platforms. Nektar PEGylation and pulmonarytechnology, expertise, and manufacturing capabilities have enabled tenapproved products for partners, which include the leading pharmaceutical andbiotechnology companies. Nektar also develops its own products by applying itsPEGylation and pulmonary technology platforms to existing medicines with theobjective to enhance performance, such as improving efficacy, safety andcompliance.To access the conference call, follow these instructions: Dial: (866) 314-5232 (U.S.); (617) 213-8052 (international) Passcode: 94561493 (Howard Robin is the host)
SOURCE Nektar Therapeutics